back to articles
Pharma: Reaching the Tipping Point
Date of publication: September 28, 2009
The pharmaceutical industry is experiencing troubling times. An unprecedented number of “blockbuster” drugs are going off patent, and the lack of replacements in the pipeline is leading to near flat growth projections in major markets. Productivity in R&D is declining, as are yields on sales and marketing investment. Despite the industry’s phenomenal contribution to health and wellbeing, its public reputation is tarnished, hampered by frequent multi-billion dollar lawsuits and a failure to demonstrate the value it brings.